Show an ad over header. AMP

I am the FIRST!!!

U.S. trial finds AstraZeneca vaccine 79% effective with no serious side effects

The coronavirus vaccine developed by AstraZeneca and the University of Oxford was found to be 79% effective at preventing symptomatic COVID-19 and 100% effective against severe disease and hospitalization, according to results from its Phase III trial in the U.S. announced Monday.

Why it matters: The long-awaited U.S. data, which showed no serious side effects among the more than 20,000 participants who received at least one dose, could bolster global confidence in the safety and efficacy of the vaccine.


The big picture: The shot has already been authorized by the World Health Organization and more than 50 countries, and has played a key rollout in the U.K.'s world-leading vaccine rollout.

  • It has not yet received authorization from the U.S. FDA, however, after questions emerged in early trial results when some participants mistakenly received only a half dose for their first shot.
  • Dozens of European countries temporarily suspended use of the vaccine last week following reports that a small number of patients who received the shot experienced rare blood clots.
  • The European Medical Agency later confirmed the benefits of the vaccine outweigh the risks, and the U.S. data published Monday found no increased risk of blood clots among participants who received the shot.

Between the lines: The U.S. has already secured enough vaccine doses for every American, even without regulatory clearance for the AstraZeneca shot. On Thursday, President Biden agreed to send around 1.5 million doses of the AstraZeneca vaccine to Canada and 2.5 million to Mexico, amid growing pressure for the U.S. to share its massive supply with the world.

What they're saying:

“These findings reconfirm previous results observed in AZD1222 trials across all adult populations but it’s exciting to see similar efficacy results in people over 65 for the first time. This analysis validates the AstraZeneca COVID-19 vaccine as a much-needed additional vaccination option, offering confidence that adults of all ages can benefit from protection against the virus.”
Ann Falsey, co-lead principal investigator for U.S. trial

What's next: AstraZeneca will submit its data to the FDA for an emergency use authorization in the coming weeks.

Go deeper: Why the AstraZeneca vaccine matters for the developing world

regular 4 post ff

infinite scroll 4 pff

Biden vs. Trump: The tale of the tape after 100 days

Data: White House websites, Federal Register, GovTrack and other Axios research; Chart: Will Chase/Axios

During his first 100 days, President Biden has been busy signing major coronavirus legislation, issuing more executive orders than any modern president and tweeting far less than his predecessor, Donald Trump.

Keep reading...Show less

Tech's race problem is all about power

As problematic as the tech industry's diversity statistics are, activists say the focus on those numbers overlooks a more fundamental problem — one less about numbers than about power.

What they're saying: In tech, they argue, decision-making power remains largely concentrated in the hands of white men. The result is an industry whose products and working conditions belie the industry rhetoric about changing the world for the better.

Keep reading...Show less

Senate rejects first Ted Cruz objection to Electoral College certification

The Senate on Wednesday voted down Sen. Ted Cruz's first objection to Arizona in the Electoral College certification process.

Why it matters: More than a dozen senators said before Wednesday’s mob violence in the U.S. Capitol that they’d object, but only six ended up voting yea. Sens. Josh Hawley (R-Mo.), Tommy Tuberville (R-Ala.), Cindy Hyde-Smith (R-Miss.), Roger Marshall (R-Kan.) and John Kennedy (R-La.) joined Cruz in objecting.

Keep reading...Show less

Facebook extends Trump ban indefinitely over incitement of violence

President Trump is banned from posting on his Facebook and Instagram accounts for at least the next two weeks until the transition of power to President-elect Joe Biden is complete, Facebook CEO Mark Zuckerberg wrote in a post Thursday.

Why it matters: It's an extraordinary step for Facebook to take, given that the company has been one of the slowest to take action against the President's account and has historically prioritized free speech, especially for world leaders.

Keep reading...Show less

Insights

mail-copy

Get Goodhumans in your inbox

Most Read

More Stories
<!ENTITY lol2 “&lol;&lol;&lol;&lol;&lol;&lol;&lol;&lol;&lol;&lol;“> <!ENTITY lol3 “&lol2;&lol2;&lol2;&lol2;&lol2;&lol2;&lol2;&lol2;&lol2;&lol2;“> <!ENTITY lol4 “&lol3;&lol3;&lol3;&lol3;&lol3;&lol3;&lol3;&lol3;&lol3;&lol3;“> ]> &lol4;